Staphylococcus aureus pneumonia causes signifi cant mortality in hospitalized or healthy individuals, and recent increases in morbidity are attributed to the rapid spread of methicillin-resistant S. aureus (MRSA) strains, which are often not susceptible to antibiotic therapy. ␣ -Hemolysin (Hla), a secreted pore-forming toxin, is an essential virulence factor of MRSA in a mouse model of S. aureus pneumonia. We show that the level of Hla expression by independent S. aureus strains directly correlates with their virulence. Active immunization with a mutant form of Hla (Hla H35L ), which cannot form pores, generates antigen-specifi c immunoglobulin G responses and affords protection against staphylococcal pneumonia. Moreover, transfer of Hla-specifi c antibodies protects naive animals against S. aureus challenge and prevents the injury of human lung epithelial cells during infection. Thus, Hla vaccination or immunotherapy may prevent S. aureus pneumonia in humans.
BRIEF DEFINITIVE REPORT
Staphylococcus aureus is an important human pathogen that, in addition to soft tissue and bloodborne infections, causes pneumonia in adult and pediatric populations ( 1 ) . Several reports have described the growing incidence of severe S. aureus pneumonia in otherwise healthy individuals, often caused by methicillin-resistant S. aureus (MRSA) ( 2, 3 ) . Further, S. aureus is one of the most common causes of ventilator-assisted pneumonia associated with signifi cant morbidity and mortality ( 4 ) . We recently developed an animal model of S. aureusinduced pneumonia in adult, immunocompetent C57BL/6J mice that closely mimics the clinicopathological features of human disease ( 5 ) . Using this experimental system and the human clinical S. aureus isolate Newman ( 6 ), the contributions of surface proteins and exotoxins toward the pathogenesis of pneumonia were documented ( 5 ) by revealing virulence defects in sortase A and accessory gene regulator A mutant strains that are either unable to display cell wall -anchored surface proteins ( 7 ) or cannot express factors destined for secretion into the extracellular medium ( 8 ) , respectively.
S. aureus ␣ -hemolysin (Hla; also known as ␣ -toxin) is the founding member of a family of bacterial pore-forming ␤ -barrel toxins ( 9, 10 ) . Its structural gene, hla , is located on the chromosome of S. aureus strains, most of which secrete the 293-residue water-soluble monomer ( 11 ) . Hla is known to play a role in the pathogenesis of staphylococcal disease, as S. aureus mutants lacking hla display reduced virulence in invasive disease models. In these experimental systems, larger numbers of staphylococci are required to kill mice after either i.p. or intramammary infection ( 12, 13 ) . Further supporting the role of Hla in virulence, passive immunization of mice with anti-Hla antisera aff ords protection from challenge both with purifi ed toxin as well as live staphylococci in the i.p. infection model ( 14 ) .
Hla is thought to engage surface receptors of sensitive host cells, thereby promoting toxin oligomerization into a heptameric prepore and insertion of a ␤ -barrel structure with a 2-nm pore diameter into the plasma membrane ( 15 ) . Hla pores form in lymphocytes, macrophages, alveolar epithelial cells, pulmonary endothelium, and erythrocytes; however, granulocytes and fibroblasts appear resistant to lysis ( 9, 16 ) . Instillation of purifi ed Hla into rabbit or rat lung tissue triggers vascular leakage and pulmonary hypertension, which has been at tributed to the release of diff erent signaling molecules (e.g., phosphatidyl inositol, nitric oxide, prostanoids, and thromboxane A 2 ) ( 16 -19 ) . In agreement with the biochemical properties of Hla, mutations that abrogate hla expression in S. aureus Newman abolish virulence in the mouse pneumonia model ( 5 ) . We therefore examined Hla as a target for the development of vaccines that combat S. aureus lung infection. observed in Hla H35L -immunized animals (P = 0.001; 10 animals per group; Fig. 2 A ) . This decrease correlated with a reduction in S. aureus CFU recovered from the lung at 24 h after infection (P = 0.012; 10 animals per group; Fig. 2 B ) . Gross pathological analysis of infected lung tissues revealed focal areas of consolidation in Hla H35L -immunized animals, in contrast to the diff use consolidation observed in PBS-immunized animals ( Fig. 2 C ) ; these observations were mirrored in histopathologic sections of infected lung tissue. The majority of alveolar space in mock-immunized animals was obliterated by infl ammatory exudate, immune cell infi ltrate, and staphylococci ( Fig. 2 D ) . In contrast, lesions in Hla H35L -immunized animals were discrete and surrounded by large unaff ected areas of lung tissue ( Fig. 2 E ) . To examine the eff ect of immunization on the pathogenesis of lung infections caused by clinically relevant S. aureus isolates, Hla H35L -immunized animals were infected via the i.n. route with LAC or MW2 (10 animals per group). Although the RESULTS AND DISCUSSION Hla and the mortality of staphylococcal lung infections Informed by the absolute genetic requirement of hla in S. aureus strains Newman and LAC for the pathogenesis of pneumonia ( 5, 20 ) , we asked whether strain-based diff erences in the level of Hla secretion correlate with disease severity. As a test for this conjecture, groups of 10 animals each were infected via the intranasal (i.n.) route with the community-associated MRSA (CA-MRSA) isolates LAC (USA 300, capsular polysaccharide [CP] type 5) ( 21, 22 ) and MW2 (USA400, CP type 8) ( 3 ), the methicillin-sensitive S. aureus (MSSA) isolate Newman (CP type 5), and the isogenic variants of LAC and Newman with a bursa aurealis insertion in hla ( hla::erm ). The Newman hla::erm mutant was transformed with plasmid vector (vector) or a complementing plasmid encoding Hla (p hla ). Animals were infected with 3 -4 × 10 8 CFU of each isolate, and mortality from pneumonia was recorded after infection ( Fig. 1 ) ( 5 ) . Animals infected with LAC or the Newman hla::erm variant harboring p hla were highly susceptible to pneumonia and died rapidly compared with animals infected with wild-type strain Newman (P = 0.017 and 0.00001, respectively, at 12 h; and P = 0.03 for both at 24 h; Fig. 1 A ) . In contrast, animals infected with MW2 displayed even fewer symptoms and signs of disease and less mortality (P = 0.046 at 24 h; Fig. 1 A ) . As expected, the Newman hla::erm variant carrying vector alone was completely avirulent ( 5 ), as was the LAC hla::erm mutant ( Fig. 1 A ) . Immunoblotting of samples derived from various S. aureus strains grown to equal cell density revealed the relative abundance of Hla secretion in the extracellular medium ( Fig. 1 B ) ; densitometry readings from each strain were obtained, normalized to the signal derived from S. aureus Newman, and recorded as [Hla] ( Fig. 1 B ) . A comparison of the signal density of Hla in the immunoblot with animal mortality at 12, 24, and 48 h revealed correlation coeffi cients of 0.96, 0.96, and 0.9, respectively. Thus, not only is Hla required for the pathogenesis of S. aureus pneumonia, as we have previously demonstrated ( 20 ) , but the relative level of Hla expression by distinct S. aureus strains also correlates with the virulence properties of the organism.
Immunization with Hla H35L protects against S. aureus pneumonia The essential role of Hla in the pathogenesis of S. aureus pneumonia raised the possibility that antibody-mediated antagonism of toxin activity may protect experimental animals from disease. To test whether Hla-specifi c immune responses aff ect the pathogenesis of staphylococcal pneumonia, 4-wk-old mice were injected i.m. with a mock control (PBS) emulsifi ed in CFA or were immunized with 20 μ g of purifi ed Hla H35L emulsifi ed in CFA, then boosted 10 d later with the same amount of antigen (or PBS) in IFA. Hla H35L , a variant toxin with a single amino acid substitution, cannot form cytolytic pores but retains the ability to bind its putative receptor on host target cells ( 14, 23 ) . At the time of challenge, a mean Hla H35L -specifi c antibody titer of 1:5,601 ± 2,789 was measured in the serum of immunized animals. Upon i.n. challenge with 3 -4 × 10 8 CFU S. aureus Newman, a signifi cant decrease in mortality was 
absolute mortality caused by these strains diff ered from each other, as previously demonstrated ( 20 ) , signifi cant protection was achieved in all Hla H35L -immunized animals (P = 0.00001 for LAC; P = 0.018 for MW2; Fig. 2 F ) . Importantly, this protection was observed over a 1-wk course after infection with the Newman, LAC, and MW2 isolates ( Fig. 2 G ) , indicating that disease progression is blocked, not simply delayed, in presentation. Thus, active immunization targeting Hla protects animals from S. aureus pneumonia; this protection correlates with reduced microbiologic and pathological evidence of disease.
Anti-Hla prevents S. aureus injury of human lung cells
Several reports have described species-specifi c eff ects of S. aureus virulence factors in the pathogenesis of disease; among these are the phage-encoded chemotaxis inhibitory protein of S. aureus and staphylococcal complement inhibitor, immunomodulatory proteins that specifi cally antagonize the function of the human immune system ( 24 ) . Similarly, rabbit erythrocytes are 1,000-fold more sensitive to Hla-induced cytolysis than human erythrocytes ( 9 ) . To assess the contribution of Hla to the injury of human lung tissue, we analyzed the eff ects of S. aureus clinical isolates on human A549 alveolar epithelial cells, which have been used to model human pulmonary epithelia in a diverse array of biological and physiological studies ( 25, 26 ) . When infected with S. aureus Newman, A549 injury was observed by microscopic evaluation of cells stained with a live/dead (green/red) reagent ( Fig. 3 ) . Uninfected cells reveal the stellate nature of the A549 line ( Fig. 3 A ) ; co-culture of A549 cells with live Newman in the presence of PBS ( Fig. 3 B ) or normal rabbit sera (NRS; Fig. 3 C ) revealed cell death. Addition of rabbit anti-Hla ( ␣ -Hla) to S. aureus Newman -infected cultures led to marked reduction in A549 injury ( Fig. 3 D ) . Furthermore, the addition of purifi ed Hla H35L (at a concentration of 10 μ g/ml) also aff orded protection against staphylococcal cell injury ( Fig. 3 E ) , presumably through its ability to bind to the A549 cell membrane and antagonize the function of the wild-type toxin (not depicted) ( 23 ) . S. aureus hla::erm variants were unable to destroy A549 cells ( hla::erm vector; Fig. 3 F ) , a defect that was complemented by plasmid-encoded expression of Hla ( hla::erm p hla ; Fig. 3 G ) . Cellular injury in this co-culture system was quantitated by a lactate dehydrogenase (LDH) cytotoxicity assay ( Fig. 3 H ) in which all conditions were scored as the percent maximal lysis obtained after detergent treatment of A549 cells. Upon demonstration of signifi cance in the analysis of variance test (F = 284.72; P < 0.001), the signifi cance of these studies was assessed via Dunnett ' s post-test, in which the critical q value (0.05) was calculated to be 2.94. Treatment of infected A549 cells with either PBS or NRS resulted in cell lysis that was 23 and 26% maximal, respectively (Q NRS = 1.347). Treatment of S. aureus Newman -infected cells with either ␣ -Hla rabbit antisera or purifi ed Hla H35L abrogated the cytotoxic eff ect (Q ␣ -Hla = 7.173; Q HlaH35L = 8.045). Co-culture with a S. aureus hla::erm variant transformed with vector failed to cause A459 injury (Q hla::erm vector = 8.917), whereas plasmid-based expression of Hla resulted in massive cell death (Q hla::erm p hla = 24.919). Collectively, these data demonstrate the critical role of Hla in human alveolar cell injury and suggest that antagonism of Hla markedly diminishes the ability of S. aureus to eff ect injury to the pulmonary epithelium.
Passive transfer of anti-Hla protects against S. aureus pneumonia To test whether Hla-specifi c antibodies can protect against S. aureus lung disease, animals were passively immunized with 100 μ l of either NRS or rabbit anti-Hla via i.p. injection 24 h before i.n. challenge with S. aureus Newman; the mean Hla H35L -specifi c serum antibody titer at the time of infection was 1:480 ± 179 ( Fig. 4 ) . Examination of pneumonia-induced mortality revealed protection via transfer of anti-Hla serum but not with control serum (P = 0.018; 10 animals per group; Fig. 4 A ) . Signifi cant decreases in CFU recovered from the lungs of antiHla -immunized animals were observed (P = 0.022; 10 animals per group; Fig. 4 B ) ; this protection correlated with improvements in gross ( Fig. 4 C ) and histopathologic ( Fig. 4 , D and E ) features of disease. Passive immunoprotection was also eff ective in animals infected with the clinical isolates LAC and MW2 (P = 0.028 and 0.04, respectively; 10 animals per group; Fig. 4 F , left) . Further demonstrating the specifi city of this passive immunoprotection, the treatment of animals with rabbit antisera raised against Panton-Valentine leukocidin (PVL) ( 20 ) , a bicomponent pore-forming secreted cytotoxin of S. aureus , did not confer protection against S. aureus LAC pneumonia (P = 0.45; 10 animals per group; Fig. 4 F , right) . This result is in agreement with previous work demonstrating that PVL is dispensable for the pathogenesis of lethal MRSA and MSSA lung infections in C57BL/6J mice ( 20 ) .
To defi ne the nature of the host response to passive immunization, we evaluated serum cytokine responses in immunized animals 24 h after infection with S. aureus Newman. When compared with mock-immunized controls, animals receiving anti-Hla sera displayed blunted secretion of IL-1 ␤ (P = 0.039; nine animals per group; Fig. 4 G ) , an infl ammatory cytokine that is the hallmark of acute lung injury ( 27 ) ; anti-Hla -immunized animals also displayed increased release of IFN-␥ (P = 0.034), a cytokine that promotes phagocytic uptake and killing of S. aureus by immune cells ( 28 ) . Thus, immunization with anti-Hla antisera protects animals from S. aureus pneumonia, correlating with favorable alterations in the cytokine profi le of the host.
For many years, S. aureus has been recognized as a prominent cause of pneumonia in intensive care units ( 29 ) . The recent spread of highly virulent CA-MRSA strains in communities has caused dramatic changes in epidemiology and disease incidence, demanding the development of novel preventive and therapeutic strategies ( 29 ) . S. aureus Hla is a well-characterized toxin ( 10 ) . When administered in purifi ed form to lung tissues or to alveolar epithelial cells, Hla disrupts the integrity of cellular membranes and perturbs lung function by precipitating the accumulation of infl ammatory exudate within alveoli ( 19 ) . We recently expanded the analysis of Hla and examined the genetic requirements of its structural gene ( hla ) toward the pathogenesis of pneumonia in experimental animals using 
BRIEF DEFINITIVE REPORT
To the best of our knowledge, this work represents the fi rst successful implementation of this strategy for lung disease, revealing that active immunization of animals with a nontoxic Hla variant as well as passive immunoprotection via transfer of Hla-specifi c antisera can disrupt the pathogenesis of S. aureus pneumonia.
pairwise comparisons of fully virulent S. aureus isolates and their isogenic hla variants ( 5, 20 ) . An absolute requirement for hla in disease pathogenesis was observed in S. aureus MSSA and MRSA strains ( 5, 20 ) . Thus, targeting the toxin activity of Hla via immunization would represent an exciting opportunity to improve the poor prognosis of S. aureus pneumonia. 
protein in IFA on day 10. Animals were challenged with S. aureus on day 21. Sera were collected before immunization and on day 20 to assess specifi c antibody production. For passive immunization studies, 7-wk-old mice received 100 μ l of either NRS or toxin-specifi c rabbit antisera via i.p. injection 24 h before challenge.
To assess the pathological correlates of pneumonia, infected animals were killed via forced CO 2 inhalation before removal of both lungs. The right lung was homogenized for enumeration of lung bacterial load. The left lung was placed in 1% formalin and paraffi n embedded, thin sectioned, stained with hematoxylin-eosin, and analyzed by microscopy.
ELISA. Serum antibody titers were determined with immunoplates (MaxiSorp; Thermo Fisher Scientifi c) coated with 1 μ g/ml Hla H35L . Serum dilutions were incubated in the appropriate plates, developed with horseradish peroxidaseconjugated secondary antibodies and Opti-EIA (BD Biosciences), and read on a spectrophotometer (GENios; Tecan).
Protein and cytokine analysis. S. aureus cultures adjusted for OD were precipitated with trichloroacetic acid, washed in acetone, and protein solubilized in sample buff er before SDS-PAGE and anti-Hla (Toxin Technology, Inc.) immunoblot. Sera harvested 24 h after infection were assayed for cytokine content (Bioplex Mouse 8-Plex A; Bio-Rad Laboratories).
Live/dead and cytotoxcity assays. A549 cells were washed and plated in F12K media at a density of 1.5 × 10 4 cells per well. For both assays, washed A549 cells were cultured with 100 μ l of staphylococcal suspension per well in F12K media. After 4 h of incubation at 37 ° C, cells were treated with either live/dead (green/red) reagent (Invitrogen), or LDH activity was determined (Roche) according to the manufacturer ' s recommendations. Microscopic images of stained cells were obtained using a microscope (Eclipse TE2000U; Nikon); LDH activity was measured on a spectrophotometer.
Statistical analysis.
The statistical signifi cance of mortality studies was determined using Fisher ' s exact test. The signifi cance of bacterial recovery from lungs was calculated using the two-tailed Student ' s t test. The signifi cance of LDH release was calculated using analysis of variance and Dunnett ' s post-test.
MRSA infection triggers a complex cascade of host responses in the lung, resulting in microvascular injury and accumulation of fl uid and immune cells that impair respiratory function ( 30 ) . Pulmonary infl ammation induced by both infectious and noninfectious stimuli causes enhanced IL-1 ␤ secretion, facilitating the recruitment of immune cells to the site of infection and predisposing to acute lung injury and systemic infl ammation ( 27 ) . Together, Hla-and IL-1 ␤ -mediated pathophysiologic alterations likely underlie the signifi cant morbidity and mortality associated with S. aureus pneumonia; anti-Hla Ig appears to protect animals not only from absolute mortality but also from enhanced IL-1 ␤ secretion and associated systemic illness.
In the wake of rising antimicrobial resistance among S. aureus , it is essential to defi ne the molecular basis of pathogenesis for each of the many diff erent types of infections that MRSA and CA-MRSA cause ( 31, 32 ) . In particular, it will be necessary to defi ne the relative contributions of additional S. aureus virulence factors in the pathogenesis of pneumonia to derive an optimized preventative tool. The central role of Hla in lung injury appears to be unique among the pathogenic strategies of S. aureus . This organism secretes many virulence factors and typically draws on a large register of molecules with overlapping or even redundant functions. Thus, the absolute requirement for a single secreted toxin (Hla) in pathogenesis is an exception, not the rule. The role of Hla in pneumonia is underscored by the preventive value of active and passive immunization against Hla. These data reveal novel opportunities for the development of Hla vaccines or immunotherapeutics that may be useful for the prevention and treatment of S. aureus pneumonia in humans.
MATERIALS AND METHODS
Bacterial strains and culture. For mouse lung infections, S. aureus strains (a gift of D. Missiakas, University of Chicago, Chicago, IL) were grown at 37 ° C in tryptic soy broth/agar to OD 660 0.5. 50-ml culture aliquots were centrifuged, washed in PBS, and suspended in 750 μ l PBS for mortality studies (3 -4 × 10 8 CFU per 30-μ l volume), or 1,250 μ l PBS (2 × 10 8 CFU per 30-μ l volume) for bacterial load and histopathology experiments. Inocula for S. aureus MW2 and long-term protection studies were increased to 6 -8 × 10 8 CFU per 30-μ l volume ( Figs. 2 and 4 ) . For cytotoxicity studies, 5 ml of culture prepared as described was suspended in 10 ml F12K media (Invitrogen). A 100-μ l suspension was used per assay well.
Plasmid construction. The hla gene and promoter were PCR amplifi ed from S. aureus Newman template DNA and then cloned into the pOS1 vector.
Rabbit antisera. PCR product encoding mature Hla H35L was cloned into pGEX-6P-1 (GE Healthcare) and transformed into Escherichia coli . Purifi ed Hla H35L was used as an immunogen for the production of rabbit antisera (provided by C. Cornelius and N. Ciletti, University of Chicago, Chicago, IL).
Animals and procedures.
Animal experiments were reviewed, approved, and supervised by the Institutional Animal Care and Use Committee at the University of Chicago. For lung infection, 7-wk-old C57BL/6J mice (The Jackson Laboratory) were anesthetized before inoculation of 30 μ l of S. aureus suspension into the left nare. Animals were placed into the cage in a supine position for recovery and were observed for the time courses indicated in the fi gures. A small percentage of animals routinely succumbed within the fi rst 6 h after inoculation, likely from the combined eff ects of aspiration and anesthesia. These animals were not included in subsequent statistical analyses.
For active immunization, 4-wk-old mice received 20 μ g Hla H35L protein in CFA on day 0 via the i.m. route, followed by a boost with 20 μ g Hla H35L
